Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $553.05 | 1 | 70.7% |
| Food and Beverage | $229.07 | 6 | 29.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $553.05 | 1 | $0 (2017) |
| Lilly USA, LLC | $119.60 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $38.33 | 2 | $0 (2024) |
| ABBVIE INC. | $33.67 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $26.48 | 1 | $0 (2024) |
| Amgen Inc. | $10.99 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98.48 | 4 | AstraZeneca Pharmaceuticals LP ($38.33) |
| 2018 | $10.99 | 1 | Amgen Inc. ($10.99) |
| 2017 | $672.65 | 2 | Eli Lilly and Company ($553.05) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $33.67 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.54 | General |
| 05/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.79 | General |
| 10/01/2018 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: Oncology | ||||||
| 07/26/2017 | Eli Lilly and Company | — | — | In-kind items and services | $553.05 | Research |
| Study: A PHASE 1B TRIAL TO ASSESS THE MODULATION OF BIOLOGICAL MARKERS IN PATIENTS WITH POTENTIALLY RESECTABLE SOFT TISSUE SARCOMA TREATED WITH OLARATUMAB MONOTHERAPY FOLLOWED BY OLARATUMAB PLUS DOXORUBICIN COMBINATION THERAPY | ||||||
| 06/29/2017 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $119.60 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B TRIAL TO ASSESS THE MODULATION OF BIOLOGICAL MARKERS IN PATIENTS WITH POTENTIALLY RESECTABLE SOFT TISSUE SARCOMA TREATED WITH OLARATUMAB MONOTHERAPY FOLLOWED BY OLARATUMAB PLUS DOXORUBICIN COMBINATION THERAPY | Eli Lilly and Company | $553.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 440 | 725 | $153,589 | $52,082 |
| 2022 | 6 | 411 | 689 | $139,277 | $51,745 |
| 2021 | 5 | 336 | 636 | $115,068 | $46,186 |
| 2020 | 7 | 290 | 518 | $80,348 | $29,411 |
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 246 | $45,770 | $16,747 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 159 | 275 | $38,677 | $11,748 | 30.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 62 | 62 | $27,714 | $8,191 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 49 | 49 | $16,228 | $6,575 | 40.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 42 | $11,354 | $3,817 | 33.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 32 | $7,237 | $3,121 | 43.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $6,609 | $1,882 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 234 | $37,032 | $16,731 | 45.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 85 | 86 | $40,850 | $12,821 | 31.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 155 | 268 | $36,042 | $12,280 | 34.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 31 | 31 | $9,930 | $3,997 | 40.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 45 | $11,025 | $3,393 | 30.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 25 | $4,398 | $2,523 | 57.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 86 | 293 | $44,675 | $20,786 | 46.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 148 | 241 | $32,160 | $10,997 | 34.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 55 | 55 | $26,253 | $8,472 | 32.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 32 | 32 | $9,502 | $4,226 | 44.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 15 | $2,478 | $1,704 | 68.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 82 | 232 | $34,806 | $13,482 | 38.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 111 | 184 | $23,900 | $6,543 | 27.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 41 | 41 | $11,263 | $5,229 | 46.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $5,789 | $2,063 | 35.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 12 | $1,914 | $1,048 | 54.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 13 | 16 | $806.00 | $643.48 | 79.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 19 | 20 | $1,870 | $402.80 | 21.5% |
About Dr. Benjamin Powers, MD
Dr. Benjamin Powers, MD is a Hematology & Oncology healthcare provider based in Overland Park, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1265695183.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Powers, MD has received a total of $782.12 in payments from pharmaceutical and medical device companies, with $98.48 received in 2024. These payments were reported across 7 transactions from 6 companies. The most common payment nature is "" ($553.05).
As a Medicare-enrolled provider, Powers has provided services to 1,477 Medicare beneficiaries, totaling 2,568 services with total Medicare billing of $179,424. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Overland Park, KS
- Active Since 07/10/2008
- Last Updated 06/23/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1265695183
Products in Payments
- IMBRUVICA (Drug) $33.67
- KEYTRUDA (Biological) $26.48
- Neulasta (Biological) $10.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Overland Park
Marc Hoffmann, Md, MD
Hematology & Oncology — Payments: $239,946
Sukumar Ethirajan, M.d, M.D
Hematology & Oncology — Payments: $73,982
Robert Talley, Md, MD
Hematology & Oncology — Payments: $3,009
Rachana Yendala, Md, MD
Hematology & Oncology — Payments: $2,914
Dr. Dhruv Bansal, Md, MD
Hematology & Oncology — Payments: $2,630
Richard Mckittrick, M.d, M.D
Hematology & Oncology — Payments: $1,031